MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$143.67
−1.56%Oct 19, 2026, 13:40 UTC
Halper Sadeh LLC said it is investigating whether Silence Therapeutics plc and its board obtained a fair price in the company's sale to Merck & Co., Inc. for $20.00 in cash per American Depositary Share.
Source:Oct 16, 2026, 18:00 UTC
Merck & Co., Inc. reported $18.8 billion in US revenue for Keytruda in 2025 and $22.5 billion in profits, up 16% from 2024.
Source:Oct 15, 2026, 15:00 UTC
Technology shares fell in Thursday premarket trading, including CoreWeave, Inc. down about 5%, ORACLE CORP down about 2%, MICRON TECHNOLOGY INC down nearly 4%, ADVANCED MICRO DEVICES INC down more than 2%, and NVIDIA CORP down around 2%; Walmart Inc. gained about 3% and Merck & Co., Inc. advanced more than 1%.
Source:Oct 13, 2026, 22:51 UTC
Merck shares closed at $141.98, down 2.39% from the prior close.
Source:Oct 13, 2026, 16:43 UTC
Merck & Co. announced the election of Paul J. Diaz to its board of directors, effective November 1, 2026.
Oct 13, 2026, 10:45 UTC
Merck & Co., Inc. announced that results from three pivotal clinical trials and more than 90 additional abstracts will be presented at the ESMO Congress 2026 in Madrid from October 23 to 27.
Source:Oct 12, 2026, 16:51 UTC
Tempus AI, Inc. expanded its strategic collaborations with Moderna, Inc., Merck & Co., Inc. and RECURSION PHARMACEUTICALS, INC. to advance its precision medicine business.
Source:Oct 10, 2026, 22:10 UTC
Merck & Co., Inc. presented one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig in adults with diabetic macular edema.
Oct 9, 2026, 14:44 UTC
The U.S. National Institutes of Health reportedly plans to accelerate cancer-vaccine development and clinical trials through a public-private initiative expected to begin in December.
Source:Oct 7, 2026, 12:30 UTC
Merck & Co., Inc. found Merck to infringe Halozyme's EP 2,797,622 patent and enjoined MSD AG from manufacturing, marketing, using, importing or stocking Keytruda SC in eight European markets.
Oct 7, 2026, 11:00 UTC
PeptiDream received an undisclosed milestone fee from Merck & Co., Inc. following progress in a jointly developed PCC program.
Source:Oct 6, 2026, 22:51 UTC
Merck shares closed at $141.94, up 1.72% from the previous close.
Source:Oct 5, 2026, 14:23 UTC
Vaxcyte shares spiked 57% after its lead vaccine candidate showed trial results positioning it against Pfizer and Merck.
Source:Oct 1, 2026, 10:45 UTC
Merck announced it will hold its third-quarter 2026 sales and earnings conference call on October 29, 2026.
Source:Oct 1, 2026, 05:30 UTC
The Ad Council launched "The Secret to Motherhood," a maternal mental health campaign under its "Love, Your Mind" initiative, with new public service announcements titled "What's Her Secret?" in English and Spanish.
Source:Sep 30, 2026, 22:50 UTC
Merck (MRK) shares closed at $145.31, down 2.66% from the previous day's close.
Source:Sep 30, 2026, 12:26 UTC
Merck announced that its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa.
Sep 29, 2026, 18:15 UTC
MSD, in partnership with Africa Health Business, held a high-level policy roundtable in Abuja on accelerating cervical cancer elimination in Nigeria.
Sep 29, 2026, 08:29 UTC
China's National Medical Products Administration approved Merck's subcutaneous formulation of the PD-1 inhibitor pembrolizumab (Keytruda) for 19 solid tumor indications, making it the first and only subcutaneously administered PD-1 inhibitor approved in China.
Source:Sep 28, 2026, 20:45 UTC
Merck discontinued its antibiotic Recarbrio from the U.S. market earlier in September 2026, ending supply of the three-drug combination injection approved seven years earlier for serious infections.
Source:Sep 28, 2026, 10:55 UTC
Shanghai SPR Therapeutics granted Merck exclusive worldwide rights to develop, manufacture and commercialize its preclinical oral KRAS G12D (ON) inhibitor SPR2015 in a deal worth up to $2.13 billion, including a $400 million upfront payment.
Source:Sep 28, 2026, 10:48 UTC
Merck & Co. granted SciBrunch an exclusive worldwide license to develop, manufacture and commercialize SPR2015, with SciBrunch to receive a $400 million upfront payment and total potential consideration of $2.13 billion including the upfront.
Sep 28, 2026, 10:47 UTC
Merck & Co. will record a $400 million pre-tax charge in the third quarter of 2026.
Source:Sep 12, 2026, 18:00 UTC
Tempus partnered with Merck on AI-driven precision medicine.
Source:Sep 10, 2026, 08:21 UTC
China's National Medical Products Administration approved Merck's Keytruda (pembrolizumab) for expanded use in early-stage high-risk triple-negative breast cancer in China.
Source:Sep 4, 2026, 00:42 UTC
Merck announced that China's National Medical Products Administration approved its PD-1 inhibitor Keytruda (pembrolizumab) for the neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma in adult patients with PD-L1 expression (CPS ≥1).
Source:
Page 1Next →